{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:52:33Z","timestamp":1792093953804,"version":"4.4.0"},"reference-count":99,"publisher":"The Korean Association for the Study of the Liver","issue":"3","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Arbutus Biopharma"},{"name":"Assembly Biosciences"},{"DOI":"10.13039\/100002491","name":"Bristol Myer Squibb","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Dicerna Pharmaceuticals"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clear B Therapeutics"},{"name":"Springbank Pharmaceuticals"},{"DOI":"10.13039\/100014931","name":"Arrowhead Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014931","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fujirebio Incorporation"},{"DOI":"10.13039\/100017981","name":"Sysmex Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017981","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["e-cmh.org"],"crossmark-restriction":true},"short-container-title":["Clin Mol Hepatol"],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:p>Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved clinical outcomes. However, functional cure is rarely attainable by current treatment modalities. RNA interference (RNAi) by small-interfering RNA (siRNA) and anti-sense oligonucleotide (ASO) has been studied as a novel treatment strategy for CHB. RNAi targets post-transcriptional messenger RNAs and pregenomic RNAs to reduce hepatitis B virus (HBV) antigen production and viral replication. By reducing viral antigens, host immune reconstitution against HBV may also be attained. Phase I\/II trials on siRNAs have demonstrated them to be safe and well-tolerated. siRNA is effective when given in monthly doses with different total number of doses according to different trial design, and can lead to sustainable dose-dependent mean HBsAg reduction by 2\u20132.5 log. Incidences of HBsAg seroclearance after siRNA therapy have also been reported. ASOs have also been studied in early phase trials, and a phase Ib study using frequent dosing regimen within 4 weeks could achieve similar HBsAg reduction of 2 log from baseline. Given the established efficacy and safety of nucleos(t) ide analogues (NAs), future RNAi regimens will likely include NA backbone. While the current evidence on RNAi appears promising, it remains undetermined whether the potent HBsAg reduction by RNAi can result in a high rate of HBsAg seroclearance with durability. Data on RNAi from phase IIb\/III trials are keenly anticipated.<\/jats:p>","DOI":"10.3350\/cmh.2022.0012","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T07:40:43Z","timestamp":1645083643000},"page":"408-424","update-policy":"https:\/\/doi.org\/10.3350\/crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["RNA interference as a novel treatment strategy for chronic hepatitis B infection"],"prefix":"10.3350","volume":"28","author":[{"given":"Rex Wan-Hin","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lung-Yi","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-313X","authenticated-orcid":true,"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-7725","authenticated-orcid":true,"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1902","reference":[{"key":"ref1","first-page":"383","volume-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","year":"2018"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31865-8"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13095"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.07.008"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/v13061169"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.013"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00836-20"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1122"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-020-00523-z"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/srep43838"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2021.12.013"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13608"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.01.030"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.028"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31503"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.03.044"},{"key":"ref17","first-page":"453","volume-title":"A prospective, openlabel, dose-escalation, single-center, phase 1 study for GC1102, a recombinant human immunoglobulin for chronic hepatitis B patients","author":"Lee","year":"2018"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.10.027"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/35888"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0710869105"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.171251798"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb918"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2009.02.010"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.01.031"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093686"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb780"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1716153"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0017-4"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/nature00896"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.06.034"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-1-34"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.79.2.1027-1035.2005"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)60357-1"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02151"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3010"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gki324"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2012.00102"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1089\/oli.2008.0149"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1089\/oli.2005.15.196"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1038"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/35099560"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg393"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1261\/rna.30706"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.11.002"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1021\/jm049167j"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1385\/1-59259-746-7:523"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0450-0"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0736"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840380410"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.21.11531-11535.2003"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.252783999"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/s1386-6532(05)80015-0"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.12.007"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/srep15259"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910462"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.052"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20649"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.04.019"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.11.050"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-015-1128-2"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.07.014"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/29.10.2041"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9062004"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2017.0709"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.066399"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2019.0804"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz214"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31920"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.06.002"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx632"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg139"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-71-12-3021"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.31"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0241"},{"key":"ref75","first-page":"S287","volume-title":"Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results","author":"Gane","year":"2021"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(17)31850-0"},{"key":"ref77","first-page":"S289","volume-title":"Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors","author":"Gane","year":"2021"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00191"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(18)30255-1"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.016"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.318"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31008"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323445"},{"key":"ref84","volume-title":"Bi-weekly dosing of ARB-1467 LNP siRNA in HBeAgNegative, virally suppressed patients with chronic HBV infection leads to deeper declines in HBsAg and potential association with IL28b","author":"Agarwal"},{"key":"ref85","volume-title":""},{"key":"ref86","volume-title":"Low HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729, in chronic hepatitis B patients on nucleos(t)ide analogue therapy","author":"Yuen"},{"key":"ref87","first-page":"S760","volume-title":"Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA","author":"Thi","year":"2021"},{"key":"ref88","first-page":"S761","volume-title":"Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T cell activation markers","author":"Paratala","year":"2021"},{"key":"ref89","volume-title":"HBV RNAi inhibitor RG6346 in Phase 1b-2a trial was safe, well tolerated, and resulted in substantial and durable reductions in serum HBsAg levels","author":"Yuen"},{"key":"ref90","volume-title":"Incorporation of novel siRNA chemistries significantly improves the potency and durability of HBV siRNAs in the AAV-HBV mouse model","author":"Hong"},{"key":"ref91","first-page":"S742","volume-title":"ALG-125755, a small interfering RNA (siRNA) against hepatitis B virus (HBV) effectively inhibits hepatitis B surface antigen (HBsAg) secretion in HBV cell models and the AAV-HBV mouse model","author":"Hong","year":"2021"},{"key":"ref92","volume-title":""},{"key":"ref93","volume-title":"Results after 12 weeks treatment of multiple doses of GSK3389404 in chronic hepatitis B (CHB) subjects on stable nucleos(t)ide therapy in a phase 2a double-blind, placebo-controlled study","author":"Yuen"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01513-4"},{"key":"ref95","volume-title":"Preliminary results from a phase 2 study evaluating VIR-2218 alone and in combination with pegylated interferon Alfa-2a in participants with chronic hepatitis B infection","author":"Yuen"},{"key":"ref96","volume-title":"Efficacy and safety of the siRNA JNJ-3989 and\/or the capsid assembly modulator JNJ-6379 for the treatment of chronic hepatitis B virus infection: results from the phase 2b REEF-1 study","author":"Yuen"},{"key":"ref97","first-page":"S720","volume-title":"Combination drug interactions of hepatitis B virus (HBV) small interfering RNA (siRNA) and antisense oligonucleotides (ASO) in vitro and in vivo","author":"Tan","year":"2021"},{"key":"ref98","volume-title":"Triple combination of anti-hepatitis B virus drugs demonstrates synergistic activity in vitro","author":"Tan"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.032"}],"container-title":["Clinical and Molecular Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2022-0012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2022.0012","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2022-0012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T08:13:06Z","timestamp":1657613586000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2022.0012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"URL":"https:\/\/doi.org\/10.3350\/cmh.2022.0012","relation":{},"ISSN":["2287-2728","2287-285X"],"issn-type":[{"value":"2287-2728","type":"print"},{"value":"2287-285X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"assertion":[{"value":"2022-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-17","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}